Jim Cramer Notes “Merck’s Cancer Dominance Has Been Challenged of Late By JNJ”
Key takeaways
- Jim Cramer Notes “Merck’s Cancer Dominance Has Been Challenged of Late By JNJ” Syeda Seirut Javed Tue, June 2, 2026 at 12:42 AM GMT+7 2 min read MRK Merck & Co., Inc.
- Now Merck… Monday evening, very odd… the actual 6:00 PM, hosts a meeting to review its cancer portfolio after the 2026 American Society of Clinical Oncology Conference.
- (NYSE:MRK) is a healthcare company that provides a wide range of human and veterinary pharmaceuticals, vaccines, and health solutions.
Jim Cramer Notes “Merck’s Cancer Dominance Has Been Challenged of Late By JNJ” Syeda Seirut Javed Tue, June 2, 2026 at 12:42 AM GMT+7 2 min read MRK Merck & Co., Inc. (NYSE:MRK) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week. It was one of the stocks mentioned in Cramer’s game plan, as he remarked:
Now Merck… Monday evening, very odd… the actual 6:00 PM, hosts a meeting to review its cancer portfolio after the 2026 American Society of Clinical Oncology Conference. That’s the most important cancer confab of the year. Merck’s cancer dominance has been challenged of late by JNJ. Let’s see what Merck has to say.
Merck & Co., Inc. (NYSE:MRK) is a healthcare company that provides a wide range of human and veterinary pharmaceuticals, vaccines, and health solutions. A caller asked about the stock during the May 1 episode, and Cramer responded: